Results 131 to 140 of about 342,422 (269)
Advanced Healthcare Materials, EarlyView.We develop a covalent organic framework‐loaded Traditional Chinese Medicine monomer nanodrug delivery system (ISL@bCOF) via boron‐oxygen bonds, a smart response to glucose for delivering AI‐driven isoliquiritigenin (ISL) targeting ZBP1. This dynamic release mechanism, combined with transdermal delivery technology via potent microneedles, can modulate ...
Menghan Zhou +9 more
wiley +1 more source
DataDTA: a multi-feature and dual-interaction aggregation framework for drug-target binding affinity prediction. [PDF]
Bioinformatics, 2023 Zhu Y, Zhao L, Wen N, Wang J, Wang C.
europepmc +1 more source
Prediction of Drug-Target Binding Affinity: A Regression Approach for IC50Prediction
, 2023 Since ancient times, humans have sought to combat disease through drug administration. As Science has evolved, Drug Discovery (DD) has led industries to focus solely on the production of pharmaceutical products. Currently, the pharmaceutical industry struggles to find new pharmaceutical products; however, this is becoming an increasingly difficult task
openaire +1 more source
Nanoparticle-Mediated Measurement of Target–Drug Binding in Cancer Cells
, 2016 Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels in individual cells, and drug delivery.
Hakho Lee (372660) +7 more
core +1 more source
Natural Biomaterials for Osteochondral Repair: From Source to Strategy
Advanced Healthcare Materials, EarlyView.Biological origin‐guided overview of natural biomaterials and therapeutic strategies for osteochondral tissue engineering. The circular diagram categorizes representative materials and strategies into plant/algae‐derived, microbial‐derived, animal‐derived, and human‐derived sources, centered on an osteochondral defect repair model.
Hengyu Liu +5 more
wiley +1 more source
Nanoparticle Mediated Measurement of Target-Drug Binding in Cancer Cells
, 2019 Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels In individual cells, and drug delivery.
Ullal, Adeeti V. +7 more
core +1 more source
Advanced Healthcare Materials, EarlyView.Single‐chain nanoparticles have been proposed as drug delivery carriers, but adding a tail can significantly enhance their performance. This was demonstrated using a tadpole‐like structure comprising a head prepared from a UV‐crosslinked fructose‐based glycopolymer capable of targeting GLUT receptors, combined with a PEG‐based tail. Compared with other
Hoang Yen Vo +6 more
wiley +1 more source
IEEE AccessPancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive form of pancreatic cancer, accounting for 90% of all pancreatic malignancies.
Pragya +2 more
doaj +1 more source
An albumin-derived peptide scaffold capable of binding and catalysis
, 2012 We have identified a 101-amino-acid polypeptide derived from the sequence surrounding the IIA binding site of human albumin. The polypeptide contains residues that make contact with ligands as warfarin in the parent protein, and eight cysteine residues ...
SBLATTERO, DANIELE +30 more
core +1 more source
Advanced Healthcare Materials, EarlyView.Pharmacokinetic engineering of clickable radioligands was achieved via albumin hitchhiking approach within a pretargeted radiotheranostics delivery platform. This approach reduced rapid renal elimination, expanded bioorthogonal capture window, boosted tumor uptake by ∼3.5‐fold, and improved the tumor‐to‐liver ratio by ∼6‐fold.
Xie He +9 more
wiley +1 more source